US loss of exclusivity · Neuroscience
Vyvgart
argenx
2036
US biosimilars from
2025
Today: 2026
2037
2025 worldwide sales
$4.2B
Date basis
Patent-expiry estimate
US biosimilars
No US filing found
Pharma Patent Cliff
by readouts.io
Data checked 8 October 2026 ·
Full Vyvgart timeline →